Holen Sie sich die Stockscreener-App
78.39
0.99%
-0.78
Vorhandelsmarkt:
78.51
0.12
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$79.17
Offen:
$79.55
24-Stunden-Volumen:
16.04M
Relative Volume:
1.01
Marktkapitalisierung:
$195.89B
Einnahmen:
$64.17B
Nettoeinkommen (Verlust:
$17.12B
KGV:
11.65
EPS:
6.73
Netto-Cashflow:
$18.10B
1W Leistung:
-0.71%
1M Leistung:
-17.11%
6M Leistung:
-29.71%
1J Leistung:
-37.88%
1-Tages-Spanne:
$77.72
$79.96
1-Wochen-Bereich:
$75.96
$81.99
52-Wochen-Spanne:
$75.96
$134.63
Merck Co Inc Stock (MRK) Company Profile
Firmenname
Merck Co Inc
Sektor
Telefon
908-740-4000
Adresse
2000 GALLOPING HILL ROAD, KENILWORTH, NJ
Vergleichen Sie MRK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MRK
Merck Co Inc
|
78.39 | 195.89B | 64.17B | 17.12B | 18.10B | 6.73 |
|
LLY
Lilly Eli Co
|
757.18 | 680.08B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
153.62 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
ABBV
Abbvie Inc
|
176.80 | 312.76B | 56.33B | 4.28B | 17.83B | 2.40 |
|
NVO
Novo Nordisk Adr
|
64.49 | 286.27B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
109.93 | 217.12B | 51.72B | 11.94B | 13.81B | 5.88 |
Merck Co Inc Stock (MRK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-18 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2025-02-10 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-01-08 | Herabstufung | Truist | Buy → Hold |
| 2024-12-20 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-12-04 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-11 | Herabstufung | Daiwa Securities | Buy → Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-03-11 | Herabstufung | Societe Generale | Hold → Sell |
| 2024-01-04 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-27 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-10-20 | Hochstufung | UBS | Neutral → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Hold |
| 2023-04-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-03-28 | Herabstufung | Societe Generale | Buy → Hold |
| 2023-03-13 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-03-06 | Eingeleitet | Jefferies | Buy |
| 2023-02-22 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-01-04 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-10-10 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-09-14 | Hochstufung | Berenberg | Hold → Buy |
| 2022-07-06 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2022-06-06 | Fortgesetzt | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2021-12-17 | Eingeleitet | Goldman | Buy |
| 2021-12-16 | Eingeleitet | Daiwa Securities | Neutral |
| 2021-12-13 | Herabstufung | UBS | Buy → Neutral |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-12-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-11-29 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-11-01 | Hochstufung | Argus | Hold → Buy |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-20 | Herabstufung | Argus | Buy → Hold |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-08-03 | Hochstufung | Goldman | Neutral → Buy |
| 2020-06-12 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-16 | Eingeleitet | SVB Leerink | Outperform |
| 2019-07-03 | Eingeleitet | Mizuho | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-05-13 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2018-10-16 | Bestätigt | Citigroup | Buy |
| 2018-10-09 | Fortgesetzt | Guggenheim | Buy |
| 2018-04-23 | Hochstufung | Goldman | Neutral → Buy |
| 2018-04-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-04-05 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-03-12 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2018-02-14 | Bestätigt | Leerink Partners | Mkt Perform |
| 2018-02-07 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2018-01-16 | Hochstufung | SunTrust | Hold → Buy |
Alle ansehen
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Rep. Kelly Morrison Sells Off Shares of Merck & Co., Inc. (NYSE:MRK) - Defense World
Price Over Earnings Overview: Merck & Co - Benzinga
Merck Signs Nearly $500 Million Licensing Deal With Austria-Based Cyprumed For Tablet-Based Peptide Delivery - Benzinga
April 14, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against MRK - TradingView
Merck & Co. Inc. (MRK): Among the High Growth Forever Dividend Stocks to Invest In - Yahoo Finance
Rep. Marjorie Taylor Greene Buys Merck & Co., Inc. (NYSE:MRK) Stock - Defense World
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
Merck to Integrate Medical Resources Into Microsoft's Health Care AI Platform - MarketScreener
Is Merck & Co. (NYSE:MRK) a Cheap NYSE Stock to Invest in According to Hedge Funds? - Insider Monkey
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Business Wire
What to Expect From Merck & Co.'s Next Quarterly Earnings Report - TradingView
What To Expect From Merck & Co.'s Next Quarterly Earnings Report - Barchart.com
Levi & Korsinsky Notifies Shareholders of Merck & Co., Inc. (MRK) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
MRK Investors Have Final Opportunity Today to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
Is Merck & Co., Inc. (MRK) the Best Medical Stock to Buy According to Billionaires? - Insider Monkey
MRK Deadline Tomorrow: MRK Investors Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - PR Newswire
FINAL MRK DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Merck & Co., Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. - Bluefield Daily Telegraph
MRK DEADLINE MONDAY: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Merck & Co., Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - GlobeNewswire Inc.
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Jim Cramer on Merck (MRK): Stay The Course… It’s Been a Real Tough One - Yahoo Finance
MRK STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - markets.businessinsider.com
MRK Lawsuit Alert! Class Action Lawsuit Against Merck & Company - TipRanks
Investors who lost money on Merck & Co., Inc.(MRK) should contact Levi & Korsinsky about pending Class ActionMRK - PR Newswire
Merck (MRK) Faces Shareholder Proposals Amid Market Challenges - GuruFocus
Merck (MRK) Poised for Growth with Strong Financial Performance - GuruFocus
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion - TradingView
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Class Action Filed Against Merck & Co., Inc. (MRK) Seeking Recovery for Investors – Contact - Bluefield Daily Telegraph
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - PR Newswire
Merck & Co., Inc. (MRK): A Bull Case Theory - Insider Monkey
Investor Sues Merck Executives, Board Over Misleading Comments - Bloomberg Law News
Merck & Co Inc Says CEO Robert M. Davis's 2024 Total Compensation Was $23.2 MillionSEC Filing - MarketScreener
MRK FINAL DEADLINE: ROSEN, NATIONAL TRIAL COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - TradingView
Investors who lost money on Merck & Co., Inc. (MRK) should contact The Gross Law Firm about - Bluefield Daily Telegraph
Deadline Alert: Merck & Co (MRK) Investors Who Lost Money - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Shareholders of Merck & Co., Inc. to Contact the Firm Today! - markets.businessinsider.com
Key Trends Shaping the Future of Pulmonary Arterial Hypertension Market:Merck & Co. Introduces Innovative F... - WhaTech
Merck & Co., Inc. (MRK): Among Defensive Stocks Billionaire Ken Fisher is Betting On - Yahoo Finance
2025-04-08 | MRK LAWSUIT ALERT: Levi & Korsinsky Notifies Merck & Co., Inc. Investors of a Class Action Lawsuit and Upcoming Deadline | NYSE:MRK | Press Release - Stockhouse
MRK Stock Price and Chart — NYSE:MRK - TradingView
Infertility Drugs Market Is Booming Worldwide 2025-2032 | Merck & Co., Inc., Ferring Pharmaceuticals - openPR.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Merck & Co., Inc. to Contact the Firm Today! - markets.businessinsider.com
Goldman Sachs raises Merck stock rating to Buy, target to $103 - Investing.com
Lost Money on Merck & Co., Inc. (MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
MRK Deadline: MRK Purchasers with Losses in Excess of $100K Have Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit - Morningstar
MRK FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important April 14 Deadline in Securities Class Action – MRK - TradingView
Merck & Co., Inc. Sued for Securities Law Violations - GlobeNewswire
Rising Leaders 2025: Partnerships Propel Crystal Qin’s LaNova To Record-Breaking Merck Deal - insights.citeline.com
Finanzdaten der Merck Co Inc-Aktie (MRK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.43%
0.77%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):